Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT01174121	TitleImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer	Phase Phase 2	Date Added 2010-08-03	Location Maryland, United States	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Aldesleukin, Cyclophosphamide, Fludarabine, Pembrolizumab (Keytruda), Young TIL	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05107674	TitleA Study of NX-1607 in Adults With Advanced Malignancies	Phase Phase 1	Date Added 2021-11-04	Location California, United States Colorado, United States Illinois, United States North Carolina, United States Oklahoma, United States Texas, United States Virginia, United States Washington, United States United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs NX-1607	Tags MSS/ MMRp
NCT ID NCT02693535	TitleTAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	Phase Phase 2	Date Added 2016-02-26	Location Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Hawaii, United States Illinois, United States Indiana, United States Maine, United States Michigan, United States Nebraska, United States New Hampshire, United States New Mexico, United States New York, United States North Carolina, United States North Dakota, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs Abemaciclib, afatinib, Atezolizumab and PHESGO, Atezolizumab and Talazoparib, Crizotinib, Entrectinib, Larotrectinib, Nivolumab and Ipilimumab, Olaparib, palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab and Pertuzumab, Tucatinib plus Trastuzumab Subcutaneous (SC), Vemurafenib and Cobimetinib, Cotellic, Herceptin, Perjeta, Zelboraf	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05299840	TitleImpact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer	Phase Not Applicable	Date Added 2022-03-29	Location France	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03297606	TitleCanadian Profiling and Targeted Agent Utilization Trial (CAPTUR)	Phase Phase 2	Date Added 2017-09-29	Location Canada	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Axitinib, Bosutinib, Crizotinib, Dasatinib, Erlotinib, Nivolumab plus Ipilimumab, Olaparib, palbociclib, Sunitinib, Temsirolimus, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04550897	TitleA Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients	Phase Phase 1	Date Added 2020-09-16	Location Norway	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs BM7PE	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04535024	TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer	Phase Phase 2	Date Added 2020-09-01	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Sintilimab	Tags MSS/ MMRp
NCT ID NCT05291156	TitleCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy	Phase Phase 2	Date Added 2022-03-22	Location Italy	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Avelumab, cetuximab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03476681	TitleStudy of NEO-201 in Solid Tumors Expansion Cohorts	Phase Phase 1	Date Added 2018-03-26	Location Maryland, United States Virginia, United States	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs NEO-201 in combination with pembrolizumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05292417	TitleRadiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRC	Phase Phase 2	Date Added 2022-03-23	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Fruquintinib, GM-CSF, Sintilimab	Tags MSS/ MMRp

Showing 71 to 80 of 299 entries